Table 1.
CLDN18.2 expression and correlation with clinico-pathological patient characteristics
| Characteristic | Variable | Total valid | CLDN18.2 expression | p value | |
|---|---|---|---|---|---|
| [N (%)] | Positive [N (%)] |
Negative [N (%)] |
|||
| Age | < 68 | 234 (49.4) | 108 (46.2) | 126 (53.8) | 0.094 |
| ≥ 68 | 240 (50.6) | 92 (38.3) | 148 (61.7) | ||
| Gender | Female | 179 (37.2) | 72 (40.2) | 107 (59.8) | 0.506 |
| Male | 302 (62.8) | 131 (43.4) | 171 (56.6) | ||
| Localization | Proximal | 145 (31.0) | 60 (41.4) | 85 (58.6) | 0.840 |
| Distal | 323 (69.0) | 137 (42.4) | 186 (57.6) | ||
| Laurén phenotype | Intestinal | 252 (52.5) | 114 (45.2) | 138 (54.8) | 0.167 |
| Diffuse | 145 (30.2) | 55 (37.9) | 90 (62.1) | ||
| Mixed | 31 (6.5) | 16 (51.6) | 15 (48.4) | ||
| Unclassified | 52 (10.8) | 17 (32.7) | 35 (67.3) | ||
| Mucin type | Intestinal | 122 (29.0) | 29 (23.8) | 93 (76.2) | < 0.001* |
| Gastric | 64 (15.2) | 32 (50.0) | 32 (50.0) | ||
| Mixed | 162 (38.5) | 78 (48.1) | 84 (51.9) | ||
| Unclassified | 73 (17.3) | 41 (56.2) | 32 (43.8) | ||
| T category | T1 | 58 (12.1) | 25 (43.1) | 33 (56.9) | 0.703 |
| T2 | 53 (11.0) | 21 (39.6) | 32 (60.4) | ||
| T3 | 195 (40.6) | 81 (41.5) | 114 (58.5) | ||
| T4 | 174 (36.3) | 76 (43.7) | 98 (56.3) | ||
| N category | N0 | 136 (28.5) | 60 (44.1) | 76 (55.9) | 0.758 |
| N1 | 67 (14.0) | 27 (40.3) | 40 (59.7) | ||
| N2 | 84 (17.6) | 29 (34.5) | 55 (65.5) | ||
| N3 | 190 (39.8) | 86 (45.3) | 104 (54.7) | ||
| M category | 0 | 387 (80.5) | 159 (41.1) | 228 (58.9) | 0.352 |
| 1 | 94 (19.5) | 44 (46.8) | 50 (53.2) | ||
| UICC stage | I | 78 (16.4) | 33 (42.3) | 45 (57.7) | 0.716 |
| II | 107 (22.4) | 46 (43) | 61 (57) | ||
| III | 198 (41.5) | 79 (39.9) | 119 (60.1) | ||
| IV | 94 (19.7) | 44 (46.8) | 50 (53.2) | ||
| L category | L0 | 214 (48.1) | 88 (41.1) | 126 (58.9) | 0.773 |
| L1 | 231 (51.9) | 99 (42.9) | 132 (57.1) | ||
| V category | V0 | 394 (88.7) | 160 (40.6) | 234 (59.4) | 0.225 |
| V1 | 50 (11.3) | 25 (50.0) | 25 (50.0) | ||
| Grading | G1/G2 | 116 (24.3) | 49 (42.2) | 67 (57.8) | 1.000 |
| G3/G4 | 361 (75.7) | 153 (42.4) | 208 (57.6) | ||
| R status | R0 | 402 (87.2) | 160 (39.8) | 242 (60.2) | 0.0231,2 |
| R1 & 2 | 59 (12.8) | 33 (55.9) | 26 (44.1) | ||
| H. pylori status | Negative | 341 (84.8) | 143 (41.9) | 198 (58.1) | 1.000 |
| Positive | 61 (15.2) | 26 (42.6) | 35 (57.4) | ||
| EBV status | Negative | 445 (95.5) | 179 (40.2) | 266 (59.8) | < 0.001* |
| Positive | 21 (4.5) | 17 (81.0) | 4 (19.0) | ||
| MSI status | MSS | 429 (92.3) | 179 (41.7) | 250 (58.3) | 1.000 |
| MSI | 36 (7.7) | 15 (41.7) | 21 (58.3) | ||
| HER2 status | Negative | 400 (92.2) | 173 (43.3) | 227 (56.8) | 0.0291 |
| Positive | 34 (7.8) | 8 (23.5) | 26 (76.5) | ||
| MET status | Negative | 434 (92.9) | 180 (41.5) | 254 (58.5) | 0.277 |
| Positive | 33 (7.1) | 17 (51.5) | 16 (48.5) | ||
| EpEX | Negative | 315 (70.6) | 149 (47.3) | 166 (52.7) | < 0.001* |
| Positive | 131 (29.4) | 38 (29.0) | 93 (71.0) | ||
| EpICD | Negative | 142 (31.6) | 64 (45.1) | 78 (54.9) | 0.472 |
| Positive | 307 (68.4) | 126 (41.0) | 181 (59.0) | ||
| E-cadherin | Negative | 324 (73.1) | 132 (40.7) | 192 (59.3) | 0.387 |
| Positive | 119 (26.9) | 54 (45.4) | 65 (54.6) | ||
| αvβ3 integrin | Negative | 336 (74.2) | 142 (42.3) | 194 (57.7) | 0.588 |
| Positive | 117 (25.8) | 46 (39.3) | 71 (60.7) | ||
| αvβ5 integrin | Negative | 209 (46.3) | 72 (34.4) | 137 (65.6) | 0.007* |
| Positive | 242 (53.7) | 114 (47.1) | 128 (52.9) | ||
| Lysozyme | Negative | 217 (50.5) | 66 (30.4) | 151 (69.6) | < 0.001* |
| Positive | 213 (49.5) | 115 (54.0) | 98 (46.0) | ||
EBV, Epstein-Barr virus; MSI, microsatellite instability
p values obtained via Fisher’s exact test or Kendall’s tau test.; *Significant after multiple testing correction
1Not significant after multiple testing correction. 2Not significant after multivariate analysis